Literature DB >> 6169331

Suppression of corneal allograft rejection by cyclosporin A.

J D Salisbury, B M Gebhardt.   

Abstract

Corneal allografts can elicit a host immune response that results in their destruction as functional tissues. Just as with other types of tissue allografts, effective, safe methods are needed to prevent corneal allograft rejection in patients undergoing penetrating keratoplasty. In this study, cyclosporin A, a compound of fungal origin, was tested for its capacity to suppress corneal allograft rejection in rabbits. Corneal allografts were exchanged between pairs of randomly bred albino rabbits. Some animals received retrobulbar injections and others received similar injections of the drug vehicle only. Cyclosporin A significantly prolonged corneal allograft survival. All the allografts in untreated eyes were rejected within 40 days; four (45%) of the nine allografts in treated eyes survived more than 70 days. Cyclosporin A alone was less effective in suppressing allograft rejection in heavily vascularized, inflamed graft sites. No adverse side effects were seen when it was injected locally into the rabbit eye. We conclude that in the acute graft model in this study, cyclosporin A is a safe, potent immunosuppressive agent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6169331     DOI: 10.1001/archopht.1981.03930020514024

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  11 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Laser photocoagulation for corneal stromal vascularization.

Authors:  V S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  1992

3.  Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

4.  Liposome-bound cyclosporine: retinal toxicity after intravitreal injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

Review 5.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

6.  Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields.

Authors:  K Mahlberg; R J Uusitalo; B Gebhardt; H E Kaufman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

7.  Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect.

Authors:  B Foets; L Missotten; P Vanderveeren; W Goossens
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

8.  The effect of topical cyclosporin A on the rabbit cornea. A clinical and electron microscopic study.

Authors:  W Behrens-Baumann; S Theuring; H Brewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

9.  Cyclosporin A: tissue levels following topical and systemic administration to rabbits.

Authors:  T A Bell; A G Hunnisett
Journal:  Br J Ophthalmol       Date:  1986-11       Impact factor: 4.638

10.  Penetration of 2% cyclosporin eyedrops into human aqueous humour.

Authors:  M Diaz-Llopis; J L Menezo
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.